Skip to main content
. 2023 Feb 6;9(1):00484-2022. doi: 10.1183/23120541.00484-2022

TABLE 1.

Stanford cohort patient characteristics in high 4-year risk and low 4-year risk groups. Continuous data are compared using a t-test and categorical variables by Chi-squared test

High 4-year risk Low 4-year risk Two-tailed p-value
Sample size 74 93
Age (years) 52.7±15.5 47.0±14.3 0.015
Female (%) 71.6 75.3
Race
 White 42 53 0.992
 Asian 10 24
 Hispanic 11 11
 Black 5 3
 Other 6 2
PAH subtype
 Connective tissue disease 25 27 0.997
 Idiopathic PAH 19 27
 Drug and toxins 13 15
 Congenital heart disease 8 17
 Portopulmonary hypertension 8 4
 Hereditary PAH 1 3
NYHA functional class
 Class I 4 5 0.942
 Class II 11 42
 Class III 46 37
 Class IV 13 9
Haemodynamics
 mPAP (mmHg) 50.8±16.2 50.9±16.6 0.969
 PVR (dyn·s·cm−5) 11.2±7.14 11.3±6.59 0.925
 Cardiac index (L·min−1·m−2) 2.27±0.82 2.24±0.67 0.795
 Mean right atrial pressure (mmHg) 9.70±6.33 7.89±4.78 0.037
 PCWP (mmHg) 12.2±5.72 10.5±4.09 0.027
Timing from
 Diagnosis (years) 3.1±3.9 4.5±5.4 0.053
 Symptom onset (years) 4.4±4.8 6.0±5.4 0.051
Therapy
 Treatment-naïve 23 28 0.999
 Monotherapy 21 28
 Dual therapy 22 26
 Triple therapy 8 11

Data are presented as n or mean±sd, unless otherwise stated. PAH: pulmonary arterial hypertension; NYHA: New York Heart Association; mPAP: mean pulmonary artery pressure; PVR: pulmonary vascular resistance; PCWP: pulmonary capillary wedge pressure.